Title:
ANTIBODY BINDING TO PD-L1 AND CLDN18.2 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/221935
Kind Code:
A1
Abstract:
The present invention provides an antibody. The antibody can specifically bind to human CLDN18.2 and human PD-L1. The present invention further provides a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody, a host cell and a preparation method therefor. The present invention also provides a diagnosis and treatment method using the antibody of the present invention.
Inventors:
QIAN XUEMING (CN)
GU YI (CN)
TENG FEI (CN)
LI HONGJUN (CN)
GUO HUANHUAN (CN)
GU YI (CN)
TENG FEI (CN)
LI HONGJUN (CN)
GUO HUANHUAN (CN)
Application Number:
PCT/CN2023/094266
Publication Date:
November 23, 2023
Filing Date:
May 15, 2023
Export Citation:
Assignee:
SUZHOU TRANSCENTA THERAPEUTICS CO LTD (CN)
TRANSCENTA HOLDING LTD (KY)
TRANSCENTA THERAPEUTICS INC (US)
TRANSCENTA HOLDING LTD (KY)
TRANSCENTA THERAPEUTICS INC (US)
International Classes:
C07K16/28; A61K39/395; A61P31/00; A61P35/00; A61P37/00; A61P37/02; A61P37/04; C07K19/00; C12N1/19; C12N15/63
Domestic Patent References:
| WO2021218874A1 | 2021-11-04 | |||
| WO2021032157A1 | 2021-02-25 |
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: